Is CJC-1295 with ipamorelin the same idea?

Yes in mechanism: CJC-1295 is a GHRH analog and ipamorelin a ghrelin-receptor agonist. That pair has not been tested in a published human study either.

Does a bigger GH pulse mean more benefit?

Not necessarily. The studies above measured GH in the blood over a few hours, not body composition or health outcomes.

Are these combinations allowed in sport?

No. WADA prohibits GHRH analogs and growth hormone secretagogues at all times (S2).

Why tesamorelin pairs with ipamorelin and not with sermorelin

Name: Why Tesamorelin Pairs With Ipamorelin, Not Sermorelin
Published: 2026-10-22

Two receptors, one ceiling, and the combinations no one has tested in people.

Checked 2026-10-22 Researched and written by Kymata Health Editorial · Sources cited inline Report an error

Short answer

Tesamorelin and sermorelin are both GHRH analogs: they press the same pituitary receptor, whose response tops out at a low dose. Ipamorelin acts on a different receptor, the ghrelin receptor. In healthy adults, a GHRH plus a ghrelin-receptor agonist released more GH than either alone. Tesamorelin with ipamorelin itself has never been tested.

What receptors do these peptides act on?

Tesamorelin, sermorelin and CJC-1295 are analogs of GHRH, the hypothalamic hormone that switches on growth hormone release. They bind the GHRH receptor, a pituitary receptor that signals through cAMP (Mayo 1992, Mol Endocrinol).

Ipamorelin, GHRP-2, GHRP-6, hexarelin and MK-677 act on a separate receptor, the growth hormone secretagogue receptor (GHS-R1a), which is also the ghrelin receptor. It sits in the hypothalamus as well as the pituitary (Howard 1996, Science). Ipamorelin works through it, not through the GHRH receptor (Raun 1998, Eur J Endocrinol).

Why are a GHRH analog and a ghrelin-receptor agonist combined?

Because in people the two routes add up, and at test doses often more than add up. In 11 healthy adults given IV doses, the GH released was 484 units after GHRH alone, 1,435 after GHRP-6 alone and 3,772 after both (Popovic 1995, JCEM). Two other groups found the same pattern (Pombo 1995, JCEM; Ramos-Dias 1996, JCEM), and the first report of the synergy dates from 1990 (Bowers 1990, JCEM).

Part of the reason is where the ghrelin-receptor route acts. With the pituitary stalk cut, GHRP-6 released almost no GH and the combination lost its extra effect, so much of its action runs through the hypothalamus (Popovic 1995, JCEM). It also slips past somatostatin, the body's brake on GH: under a somatostatin analog, the GH response to GHRH fell by 38% while the response to GHRP-2 did not change (Dimaraki 2003, Am J Physiol).

The effect has limits. When both were given at full doses, one study found the combination no larger than the sum of the two alone (Tiulpakov 1995, Clin Endocrinol). During hard exercise, GHRH and GHRP-2 simply added to each other (Maas 2000, Med Sci Sports Exerc).

GHRH, a GHRP, and both, in healthy adults

IV test doses in healthy adults; units differ by study (area under the GH curve or peak GH), so compare within a row. The dashed line is GHRH alone plus the GHRP alone: a combined bar past it is more than additive. The last row, at full doses of both, is not. (Popovic 1995, JCEM; Pombo 1995, JCEM; Ramos-Dias 1996, JCEM; Tiulpakov 1995, Clin Endocrinol)

Why do tesamorelin and sermorelin not stack?

Both press the same receptor, and that receptor's response saturates early. In 73 young adults, a GHRH dose of 1 µg/kg was enough for a maximal GH response (Gelato 1984, JCEM); another study saw no higher peak from 0.1 to 10 µg/kg, only a longer response (Vance 1984, JCEM).

So a second GHRH analog on top of the first is expected to add little. No study has given two GHRH analogs together, so this is an inference from the dose-response curves, not a trial result.

Has tesamorelin been tested with ipamorelin?

No. PubMed and ClinicalTrials.gov list no human study of tesamorelin given with ipamorelin, another GHRP or MK-677, and none of the registered tesamorelin trials has such an arm (searched 2026-10-22). The case for the pair rests on the other agents above.

Ipamorelin's own human data are thin: one study of IV infusions in healthy men, with a half-life of about 2 hours and a GH peak about 40 minutes after the infusion began (Gobburu 1999, Pharm Res). Its selectivity for GH over cortisol was shown in pigs (Raun 1998, Eur J Endocrinol).

Frequently asked questions

Questions

Is CJC-1295 with ipamorelin the same idea?: Yes in mechanism: CJC-1295 is a GHRH analog and ipamorelin a ghrelin-receptor agonist. That pair has not been tested in a published human study either.
Does a bigger GH pulse mean more benefit?: Not necessarily. The studies above measured GH in the blood over a few hours, not body composition or health outcomes.
Are these combinations allowed in sport?: No. WADA prohibits GHRH analogs and growth hormone secretagogues at all times (S2).

Not medical advice This page summarises published labels and studies. It is not a recommendation to use any product; a clinician decides.